Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: A retrospective analysis. Issue 7 (4th March 2019)

• Record Type: Journal Article
• Authors: Boglione, Lucio; Lupia, Tommaso; Cariti, Giuseppe; Ghisetti, Valeria; Milia, Maria Grazia; Burdino, Elisa; Di Perri, Giovanni
• Is Part Of: Journal of medical virology. Volume 91:Issue 7(2019)
• Page Start: 1329
• Page End: 1334
• Publication Date: 2019-03-04
• Subjects: clinical outcomes -- hepatitis D virus -- immigrants -- pegylated interferon -- quantitative hepatitis B surface antigen; Virology -- Periodicals; 616
• DOI: 10.1002/jmv.25438
• Languages: English
• ISSNs: 0146-6615

Abstract

Abstract: Chronic hepatitis delta (CHD) is the most severe chronic hepatitis, with no satisfactory treatment options and severe clinical outcomes. This infection is frequent in the migrant subjects from endemic areas, especially from Africa and East‐Europe. The pegylated (PEG)‐interferon α (IFN) is limited by side effects and poor response. In this retrospective analysis, we reported our experience of treatment with PEG‐IFN in a cohort of immigrant patients affected by CHD. We evaluated the virological responses are as follows: complete response (CR; clearance of hepatitis B surface antigen [HBsAg] and hepatitis D virus [HDV]‐RNA), partial response (PR; HBsAg clearance with HDV‐RNA+), and null response (NR; HBsAg and HDV‐RNA+). Clinical outcomes were clinical stabilization, disease progression, hepatic decompensation, hepatocellular carcinoma (HCC), death, and liver transplantation. Forty‐six patients were included. At the end of treatment (ET), 11 patients gained a CR (23.9%), 10 were PR (21.7%), and 16 were NR (34.8%). After 1 year, 10 remained with CR (21.7%), after 2 years, 9 (19.5%), and at 3 years, 8 (17.4%). Relapse rate was 2.2%, 4.4%, and 6.5% at year 1, 2, and 3, respectively. Favorable factors were CR at the ET (odds ratio [OR] = 4.559, 95% confidence interval [CI]: 2.219‐7.116; P = 0.003), PEG‐IFN course greater than 1 (OR = 1.240, 95% CI: 0.998‐4.839; P = 0.012), prolonged treatment (OR = 1.276, 95% CI: 0.816‐3.108; P = 0.018), quantitative hepatitis B surface antigen (qHBsAg) decline at 12 weeks greater than 0.5 log IU/mL (OR = 4.816, 95% CI: 2.190‐8.194; P < 0.001). The unfavorable factors were cirrhosis (OR = 3.122, 95% CI: 1.466‐4.190; P = 0.012), active hepatitis B virus (OR = 2.334, 95% CI: 1.788‐3.992; P = 0.018), NR at ET (OR = 6.998, 95% CI: 5.987‐11.404; P < 0001). Treatment of CHD is limited by poor virological response; is NR unfavorable outcomes were unavoidable. No other treatment options were available.